MDACT: A new principle of adjunctive cancer treatment using combinations of multiple repurposed drugs, with an example regimen
Creators: name: Kast, Richard E.
name: Alfieri, Alex
name: Assi, Hazem I.
name: Burns, Terry C.
name: Elyamany, Ashraf M.
name: Gonzalez-Cao, Maria
name: Karpel-Massler, Georg
name: Marosi, Christine
name: Salacz, Michael E.
name: Sardi, Iacopo
name: Van Vlierberghe, Pieter
name: Zaghloul, Mohamed S.
name: Halatsch, Marc-Eric
Publisher: name: Universität Ulm
Year: 2022
Subjects: subject: colon cancer
subject: CUSP9v3
subject: lung cancer
subject: multidrug regimen
subject: repurposing
subject: DDC 610 / Medicine &amp; health
subject: Cholangiocarcinoma; Drug therapy
subject: Colonic neoplasms; Drug therapy
subject: Glioblastoma; Drug therapy
subject: Lung neoplasms; Drug therapy
subject: Antineoplastic agents
subject: Gallengangkrebs
subject: Glioblastom
subject: Colonkrebs
subject: Lungenkrebs
subject: Pharmakotherapie
subject: Chemotherapie

description: Simple Summary We present eight core attributes of cancer growth that we must address for a more effective treatment than we currently have. To do this we outline why a regimen simultaneously using many different drugs will be needed. At our current state of knowledge, even adding two or three drugs will not counter all the growth attributes of a currently incurable cancer. We show in this paper, the details of how an example six drug regimen, when added alongside of current traditional treatments, might inhibit enough of the eight core growth driving elements to allow those standard treatments to be more effective. We further show how medicines from general medical practice used to treat pain, fungal infections, psychosis, leprosy and other non-cancer related illnesses can be repurposed to block cancer cells’ survival pathways and growth drives. Abstract In part one of this two-part paper, we present eight principles that we believe must be considered for more effective treatment of the currently incurable cancers. These are addressed by multidrug adjunctive cancer treatment (MDACT), which uses multiple repurposed non-oncology drugs, not primarily to kill malignant cells, but rather to reduce the malignant cells’ growth drives. Previous multidrug regimens have used MDACT principles, e.g., the CUSP9v3 glioblastoma treatment. MDACT is an amalgam of (1) the principle that to be effective in stopping a chain of events leading to an undesired outcome, one must break more than one link; (2) the principle of Palmer et al. of achieving fractional cancer cell killing via multiple drugs with independent mechanisms of action; (3) the principle of shaping versus decisive operations, both being required for successful cancer treatment; (4) an idea adapted from Chow et al., of using multiple cytotoxic medicines at low doses; (5) the idea behind CUSP9v3, using many non-oncology CNS-penetrant drugs from general medical practice, repurposed to block tumor survival paths; (6) the concept from chess that every move creates weaknesses and strengths; (7) the principle of mass—by adding force to a given effort, the chances of achieving the goal increase; and (8) the principle of blocking parallel signaling pathways. Part two gives an example MDACT regimen, gMDACT, which uses six repurposed drugs—celecoxib, dapsone, disulfiram, itraconazole, pyrimethamine, and telmisartan—to interfere with growth-driving elements common to cholangiocarcinoma, colon adenocarcinoma, glioblastoma, and non-small-cell lung cancer. gMDACT is another example of—not a replacement for—previous multidrug regimens already in clinical use, such as CUSP9v3. MDACT regimens are designed as adjuvants to be used with cytotoxic drugs.